DUBLIN, Ireland, August 7, 2013 /PRNewswire/ --
Research and Markets (http://www.researchandmarkets.com/research/33f35n/pain_therapeutics) has announced the addition of new report "Pain Therapeutics - Drugs, Markets and Companies" to their offering.
This report describes the latest concepts of pathomechanisms of pain as a basis for management and development of new pharmacotherapies for pain. Major segments of the pain market are arthritis, neuropathic pain and cancer pain. Because pain is a subjective sensation, it is difficult to evaluate objectively in clinical trials. Various tools for pain measurement are described, including brain imaging.
Most of the currently used analgesic drugs fall into the categories of opioids and non-steroidal anti-inflammatory drugs such as COX-2 inhibitors. Non-opioid analgesics include ketamine, a N-methyl-D-aspartate receptor antagonist. Adjuvant analgesics include antidepressants and antiepileptic drugs used for the treatment of neuropathic pain. Management of pain is multidisciplinary and includes both pharmacological and non-pharmacological methods such as acupuncture, transcutaneous electrical nerve stimulation and surgery. Various pain syndromes require different approaches in management, for example, the main category of drugs for migraine are triptans such as sumatriptan.
Drug delivery is an important consideration in pain treatment. Controlled release preparations provide a steady delivery of analgesics. Well-known non-injection methods such as transdermal, pulmonary and intranasal application have been used. Topical analgesics and local anesthetics are also available. Devices such as implanted pumps are used for delivery of drugs such as opioids intrathecally (introduction into spinal subarachnoid space by lumbar puncture) in patients with cancer pain.
Advances in molecular and biological techniques are markedly advancing our understanding of pain. Understanding the pathophysiology of pain is an important factor in discovery of rational therapies for pain. Advances in pharmacogenomics and pharmacogenetics are enabling the development of personalized approaches to the management of pain.
Over 500 companies have been identified to be involved in developing or marketing pain therapeutics and 164 of these are profiled in the report along with 149 collaborations. These are a mix of pharmaceutical companies and biotechnology companies.
The worldwide analgesic markets were analyzed for the year 2012 and projected to 2022. Calculations are based on the epidemiology of various painful conditions and the development of analgesic drugs and devices. Unfulfilled needs for analgesics are identified and strategies are outlined to develop markets for analgesic drugs. The report is supplemented with 66 tables, 18 figures, and 600 selected references to the literature.
Key Topics Covered:
1. Basic Aspects of Pain
2. Assessment of Pain and Analgesics
3. Pharmacotherapy of Pain
4. Management of Pain
5. Drug Delivery for Pain
6. Drug Development for Pain
7. Legal and regulatory issues of pain management
8. Pain Markets
9. Future of Pain Therapeutics
10. Companies Involved in Pain Therapeutics
For more information visit http://www.researchandmarkets.com/research/33f35n/pain_therapeutics
|SOURCE Research and Markets|
Copyright©2012 PR Newswire.
All rights reserved